Rezolute (RZLT) news
Recent news
Rezolute - Primary endpoint is 50% reduction in glucose infusion rate within 8 weeks
Rezolute, Inc. (Nasdaq: RZLT) recently reported outcomes from its Phase 3 sunRIZE trial of ersodetug for the treatment of congenital hyperinsulinism (HI). The study aimed to evaluate the safety and efficacy of the therapy, with a primary endpoint of a 50% reduction in glucose infusion rate within 8…
AInvest Wire · 11h agoRezolute announces completion of enrollment in phase 3 uplift study of Ersodetug in tumor hyperinsulinism
Rezolute, Inc. (Nasdaq: RZLT) announced that it has completed enrollment in its Phase 3 upLIFT study of Ersodetug for the treatment of tumor hyperinsulinism (HI) . The study, which is evaluating the safety and efficacy of Ersodetug in patients with hypoglycemia caused by insulinoma or non-islet…
AInvest Wire · 11h agoRezolute - On track to report phase 3 uplift study topline results in tumor HI this quarter
AInvest Wire · Oct 5, 2026Rezolute announces FDA recommendation to hold a pre-BlA meeting
AInvest Wire · Oct 5, 2026Rezolute announces FDA recommendation to hold a pre-BlA meeting as a precursor to submitting a biologics license application (BLA) for congenital hyperinsulinism
AInvest Wire · Oct 5, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.